DRUG
Cognitive and Neural Effects of ARA290
Status
Completed
Phase
Phase 1 / Phase 2
Enrollment
36
Locations
1
Results
Not posted
Publications
3
Study summary
What the protocol is testing.
Studies on the hormone Erythropoietin (EPO) have indicated that EPO may have antidepressant properties. However, EPO may cause serious side-effects with repeated administration (thrombosis), which limits its usefulness as an antidepressant. ARA290 is a peptide that does not have the effects of EPO on blood cells but may still have its effect on brain function. In an attempt to replicate previous findings with (a single dose of) EPO in healthy volunteers, we study the effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers. We hypothesize that a single dose of ARA290 will lead to a positive shift in information processing compared to placebo, 7 days post-administration.
Full detailed description
SUMMARY Rationale: Studies on the cognitive and neuronal effects of a single administration of Erythropoietin (EPO) in healthy volunteers and in depressed patients have suggested that EPO may have antidepressant effects. Due to its haematopoietic effects, EPO may cause serious side-effects with repeated administration, which limits its usefulness as an antidepressant. ARA290 is a peptide that does not have the haematopoietic effects of EPO but may still have its neurotrophic effects. Objective: To study the effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers 7 days post-administration. Study design: Randomized double-blind placebo-controlled experiment. Study population: Male and female healthy volunteers, n= 36; 18-35 yr old. Intervention: One group receives a single dose of 2 mg ARA290, the other group receives placebo. Main study parameters/endpoints: 1. Behavioral study: Performance on an Emotional Test battery (ETB) which has been shown sensitive to antidepressant administration in healthy volunteers. The ETB includes a measure of facial expression recognition, emotional memory and attentional vigilance. 2. Neuroimaging study: Neural processing of emotions, in particular amygdala, hippocampal and VMPFC response to viewing facial stimuli expressing negative versus positive emotions. Nature and extent of the burden and risks and benefits associated with participation: Risks: No adverse events have been associated with the administration of a single dose of 70 -2000 μg ARA290 among 36 individuals, with the exception of one individual (with an undisclosed significant prior history of fainting) who fainted shortly after the intravenous dose administration of 700 μg ARA290 and recovered without medical intervention. Fourteen individuals have participated in a multiple dosing study with no serious adverse effects. Single doses of ARA290 in patients with renal impairment did not raise a safety signal. Burden: Minimal. Emotional information processing test battery, burden comparable with playing computer games. fMRI measurement. Benefits: Probably none. Possibly transient and small improvement of mood state. Financial compensation for participating.
Interventions
Treatment arms and agents.
DRUG
Placebo
Timeline
From registration to results.
First posted
Feb 25, 2014
Study start
Feb 2012
Primary completion
Feb 2013
Study completion
Feb 2014
Results posted
Not reported
Registry updated
Feb 25, 2014
Outcomes
What the study measures.
Primary outcomes
performance on information processing test battery, particularly emotion recognition
Time frame · 1 week
Performance on an Emotional Test battery (ETB) which has been shown sensitive to antidepressant administration in healthy volunteers. The ETB includes a measure of facial expression recognition, emotional memory and attentional vigilance.
Secondary outcomes
• Performance on a task of working memory
Time frame · 1 week
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 35 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Dutch-speaking * Age 18-35 * Right-handedness * BMI 18 to 33 kg/m2 Exclusion Criteria: * Major physical illness, such as diabetes, thyroid disease, epilepsy, stroke, multiple sclerosis, pituitary disease, or any other serious medical condition. * Any current or past psychiatric disorder, including subclinical claustrophobia if severe enough to cause anxiety during scanning. * Using medication likely to interfere with the study, including OTC (over the counter) medication (e.g., St John's Wort) and benzodiazepines. * Pregnancy or breastfeeding * Use of any nicotine products or soft drugs (hash, marihuana) in the three months prior to the study * Any hard drug use (including XTC) (lifetime) * Alcohol use of more than 14 units per week or more than 4 units on any day during the week prior to the study or during the study period.
Study locations
1 registered sites.
Netherlands. Showing up to 24 locations stored in the fast local snapshot.
Leiden University Medical Center
Leiden, Netherlands
Publications
Results and literature.
Related trials
More studies on ARA-290 / Cibinetide.
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
Belfast Health and Social Care Trust · Diabetic Macular Oedema
Phase 2
Terminated
9
2024-10
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Araim Pharmaceuticals, Inc. · Neuropathy of Sarcoidosis
Phase 2
Completed
64
2017-04
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
Claes-Göran Östenson · Diabetes Type 2 · Impaired Glucose Tolerance
Phase 2
Unknown
24
2015-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.